This gene encodes a 696 amino acid protein that has homology to IL-1 receptor accessory proteins. Non-overlapping deletions and a nonsense mutation in this gene were identified in patients with ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

This study investigates the potential involvement of mutations in the IL-36 receptor antagonist (IL36RN, IL-36RA) in the ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to ...

The first direct and selective interleukin-1 (IL-1) receptor antagonist, anakinra can be used alone or in combination with any of the other DMARDs, except those in the tumor necrosis factor (TNF ...

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

Key predictors of chronic pain following motor vehicle collisions include elevated levels of acute post-traumatic stress ...